Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan Oxlumo Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Oxlumo (lumasiran) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Part B coverage of Oxlumo (lumasiran) for pediatric and adult patients with primary hyperoxaluria type 1, including requirements for diagnosis confirmation, specialist involvement, supporting documentation, and documented clinical benefit for reauthorization.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyOxlumo (lumasiran) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with medical records, PH1 confirmation by AGXT genetic testing or liver enzyme analysis, and nephrologist or urologist prescribing or consultation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    PH1Covered indication
    1 yearInitial coverage duration
    2 yearsReauthorization duration
    AGXT or liver enzymePH1 confirmation methods

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J0224Billing code
    0.5 mgBilling unit

    Coverage Criteria

    Initial Therapy Criteria

    Covered for pediatric and adult patients when all initial therapy requirements are met.

    Initial therapy

    • Covered indication: The patient has primary hyperoxaluria type 1 (PH1).
    • Diagnostic confirmation

      • PH1 is confirmed by genetic testing of the AGXT mutation.
      • PH1 is confirmed by liver enzyme analysis.
    • Specialist involvement: Oxlumo is prescribed by or in consultation with a nephrologist or urologist.
    • Supporting documentation: Medical records supporting the request are provided.

    Continuation Therapy Criteria

    Reauthorization is covered when all continuation requirements are met.

    Continuation therapy

    • Clinical benefit: Documented clinical benefit with Oxlumo compared with baseline.
    • Supporting documentation: Medical records supporting the reauthorization request are provided.

    Coverage will not be provided when the patient has a history of kidney or liver transplant and Oxlumo is intended for use in combination with Rivfloza.

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    J0224Oxlumo (lumasiran)

    Prior Authorization and Documentation

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for Oxlumo. Submit supporting medical records, confirmation of primary hyperoxaluria type 1 (PH1), and all required clinical documentation with the request.

    Prior Authorization

    Reauthorization Requirements

    For reauthorization, document clinical benefit with Oxlumo compared with baseline. Reauthorization approval is for two years.

    Documentation Required

    Medical Records Required

    Submit medical records supporting the Oxlumo request.

    Therapy Background

    Oxlumo (lumasiran) is a HAO1-directed small interfering ribonucleic acid (siRNA) therapy indicated for pediatric and adult patients with primary hyperoxaluria type 1 (PH1). It is used to lower urinary and plasma oxalate levels.

    Key Definitions

    PH1
    DefinitionPrimary hyperoxaluria type 1 (PH1) is the covered diagnosis for Oxlumo treatment.
    Genetic confirmationPH1 may be confirmed by genetic testing of the AGXT mutation.
    Enzyme confirmationPH1 may also be confirmed by liver enzyme analysis.
    Oxlumo
    Generic nameOxlumo is lumasiran.
    Therapeutic classLumasiran is a HAO1-directed small interfering ribonucleic acid (siRNA) therapy.
    Therapeutic roleOxlumo is indicated to lower urinary and plasma oxalate levels in pediatric and adult patients with primary hyperoxaluria type 1.

    Oxlumo Initial Authorization

    Oxlumo Initial Authorization

    Initial coverage is available for pediatric and adult patients with PH1 when all diagnostic, documentation, and specialist requirements are met.

    Oxlumo initial authorization

    • PH1 diagnosis confirmation

      • Primary hyperoxaluria type 1 (PH1) is confirmed by genetic testing of the AGXT mutation.
      • Primary hyperoxaluria type 1 (PH1) is confirmed by liver enzyme analysis.
    • Supporting documentation: Medical records supporting the request are provided.
    • Prescriber requirement:

    Oxlumo Reauthorization

    Oxlumo Reauthorization

    Reauthorization requires documented clinical benefit with Oxlumo compared with baseline.

    Oxlumo reauthorization

    • Clinical benefit: Documented clinical benefit with Oxlumo compared with baseline.
    • Supporting documentation: Medical records supporting the reauthorization request are provided.
    Policy Summary
    PayerGold Coast Health Plan
    PolicyOxlumo (lumasiran) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with medical records, PH1 confirmation by AGXT genetic testing or liver enzyme analysis, and nephrologist or urologist prescribing or consultation.
    SourceLink
    On This Page
    Coverage CriteriaBilling and CodingPrior Authorization and DocumentationTherapy BackgroundKey DefinitionsOxlumo Initial AuthorizationOxlumo Reauthorization
    Documentation Required

    PH1 Confirmation Required

    Document PH1 confirmation through AGXT genetic testing or liver enzyme analysis.

    Documentation Required

    Document Reauthorization Benefit

    For reauthorization, provide documentation demonstrating clinical benefit with Oxlumo compared with the patient’s baseline.

    Denial Risk

    Transplant History with Rivfloza Combination

    Coverage is excluded when the patient has a history of kidney or liver transplant and will use Oxlumo in combination with Rivfloza.

    Denial Risk

    No Documented Clinical Benefit

    Reauthorization does not meet criteria without documented clinical benefit with Oxlumo compared with baseline.

    Oxlumo is prescribed by or in consultation with a nephrologist or urologist.